Researchers at Aarhus University have built a microscopic needle from DNA that can punch through a cell’s outer membrane and deposit molecules directly into the cell interior, bypassing the defensive compartments that neutralize most drug payloads. The device, described in a study published in Advanced Science on January 9, 2026, mimics the injection machinery of bacteriophages, the viruses that attack bacteria. If the approach scales beyond lab cell lines, it could reshape how targeted therapies reach their destinations inside human cells.
Why Most Drug Payloads Never Reach Their Target
A persistent problem in drug delivery is that cells trap incoming molecules in endosomes, membrane-bound compartments that act as a first line of defense. Material caught inside endosomes is typically broken down before it can do anything useful. The Advanced Science team reports that only about 2% of an RNA payload delivered via lipid nanoparticles actually reaches the cytosol, with the rest lost to endosomal entrapment or exocytosis.
That figure aligns with broader assessments of the bottleneck. A review in Nanomedicine notes that DNA origami carriers struggle with stability and targeting, internalization efficiency, and especially the need to escape endosomes once inside cells. Separate research on mRNA therapeutics estimates that only around 5 to 10% of cargo escapes from endosomes into the cytosol, sharply limiting how much protein is produced and how long immune responses last.
The practical consequence is stark: most medicines taken up by cells never reach their intended molecular targets. For nucleic acid drugs, enzymes in endosomes and lysosomes degrade the payload before it can influence gene expression. For protein and peptide drugs, acidic conditions and proteases break them apart. This mismatch between what is administered and what actually arrives in the cytosol has driven a wave of innovation in delivery technologies, from lipid nanoparticles to polymer capsules and viral vectors.
Many of these approaches are now converging on the same conclusion: the field needs more precise control over where and when drugs cross the membrane barrier. As researchers at the Wyss Institute have argued in their overview of next-generation delivery, the next era of therapeutics will depend on vehicles that can navigate biological barriers and deposit cargo exactly where it is needed, ideally without triggering excessive immune reactions.
How the Bacteriophage-Mimetic Needle Works
Bacteriophages inject their DNA directly into the cytosol of a host cell by puncturing its membrane with a rigid tail structure. The Aarhus team replicated that principle using DNA origami, the technique of folding a long strand of DNA into a predetermined three-dimensional shape with the help of short “staple” strands. Their needle-like structure is functionalized with trastuzumab antibodies, cholesterol, protective polymers, and two fluorescent dyes, each serving a distinct role.
Trastuzumab, a monoclonal antibody used clinically against HER2-positive breast cancer, guides the needle toward cells that overexpress the HER2 receptor. By decorating the origami with multiple antibody copies, the researchers increase the likelihood that the needle will bind tightly to the cancer cell surface. Cholesterol molecules embedded along the shaft help the structure associate with and insert into the lipid bilayer of the plasma membrane, providing a hydrophobic anchor.
The protective polymer coating is designed to shield the DNA scaffold from nucleases and other degrading agents in biological fluids. DNA origami without such protection tends to fall apart in serum, one of the key challenges highlighted in prior nanomedicine reviews. By combining a rigid DNA core with a soft polymer shell, the Aarhus design aims to balance structural precision with biological resilience.
Two fluorescent dyes provide a built-in readout of what the needle is doing. A red dye labels the upper part of the structure that remains outside the cell, while a green dye is attached at the very tip via a cleavable linker. When the tip penetrates the membrane, mechanical forces and local chemistry cause the green dye to detach and diffuse into the cytosol. The red signal stays near the membrane, marking the position of the needle body.
Unlike a natural bacteriophage, the DNA needle carries no viral genome. Instead, it can be loaded with therapeutic cargo (small molecules, peptides, or nucleic acids) attached to the inner surface or tip. As reported in a related visual explainer, the concept is to ferry these molecules across the membrane and release them directly into the cell interior, bypassing the endosomal route altogether.
Evidence for Direct Cytosolic Delivery
The central claim of the Aarhus study is that the DNA needle delivers cargo straight into the cytosol rather than being swallowed into endosomes. To support this, the researchers combined confocal microscopy, time-lapse imaging, and biochemical readouts. After the needle binds to HER2-positive cells, the green fluorescence rapidly appears throughout the cell interior, while the red signal remains confined to a thin ring at the periphery, consistent with membrane association.
This spatial separation between the two dyes is critical. If the entire structure were internalized via endocytosis, both colors would move together into vesicles, producing overlapping punctate signals. Instead, the observed pattern suggests that only the tip crosses the membrane, releasing the green dye and any attached cargo into the cytosol. The red-labeled shaft appears to lodge in or rest on the membrane, echoing the way bacteriophage tails attach to bacterial surfaces.
A preprint version of the work provides additional controls, including experiments on HER2-negative cells that show minimal binding and penetration, as well as pharmacological inhibitors that distinguish membrane insertion from conventional endocytosis pathways. The authors also report cytosolic activity of delivered reporter molecules, offering functional evidence that at least some cargo avoids endosomal degradation.
However, all of this evidence comes from cultured cell lines under controlled conditions. No animal studies or in vivo pharmacokinetic data have yet been disclosed. That leaves open questions about how the needles behave in the bloodstream, how long they remain intact, and whether they accumulate in off-target tissues. The immune system’s response to repeated administration of DNA-based structures also remains to be tested.
Competing Strategies for Endosomal Escape
The Aarhus needle is one of several strategies aimed at overcoming endosomal trapping. Another approach uses DNA nanotubes that act as a “proton sponge” inside endosomes. As protons are pumped into the compartment, the nanotubes buffer the acidity and draw in counterions and water, eventually causing the membrane to swell and rupture. This mechanism was demonstrated in a study in the Proceedings of the National Academy of Sciences, where engineered DNA nanotubes facilitated the release of cargo from endosomal vesicles into the cytosol.
Other platforms rely on pH-responsive polymers that become membrane-disruptive in acidic endosomes, or on peptides derived from viruses that naturally escape from endosomal compartments. Lipid nanoparticles, the workhorses of mRNA vaccines, are being re-engineered with ionizable lipids and helper components that promote fusion with endosomal membranes. Each of these tactics seeks to exploit the endosomal environment rather than bypass it entirely.
The DNA needle takes a more direct route: instead of waiting to be internalized and then escaping, it aims to cross the plasma membrane at the outset. If successful, this could reduce the dose needed to achieve a therapeutic effect, since less cargo would be lost to degradation. It might also enable delivery to cell types that are poor at endocytosis, expanding the range of treatable tissues.
Promise, Risks, and Next Steps
Enthusiasm around the Aarhus work reflects a broader sense that drug delivery is entering a transitional phase. As one news report on the project framed it, the DNA needle represents a possible breakthrough in getting fragile molecules into cells so they can perform their tasks. If the concept generalizes beyond HER2-positive cancer cells, it could be adapted to deliver gene editors, RNA therapeutics, or protein drugs with unprecedented precision.
Yet the path from elegant in vitro experiments to approved therapies is long. DNA origami structures are complex to manufacture at scale, and ensuring batch-to-batch consistency will be essential. Regulatory agencies will scrutinize not only the safety of the payloads but also the immunogenicity and biodistribution of the delivery vehicle itself. Off-target membrane puncture could damage healthy cells, and chronic exposure to DNA-based nanostructures might provoke antibody responses that blunt efficacy or cause side effects.
Future work will likely focus on three fronts. First, researchers will need to validate the needle’s performance in animal models, tracking where it goes, how long it persists, and what fraction of cargo truly reaches the cytosol in vivo. Second, the design will need to be diversified with different targeting ligands so that other disease-relevant cell types can be addressed. Third, manufacturing processes must be refined to produce large quantities of stable, well-characterized needles under clinical-grade conditions.
For now, the DNA needle stands as a striking example of how nanoscale engineering can learn from viral biology to solve longstanding problems in medicine. By physically piercing the membrane barrier rather than trying to outwit the endosomal system, it offers a fresh route to the cell interior, one that, if its early promise holds up, could help unlock the full potential of molecular therapies.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
